Scarica l'app Stockscreener
23.39
2.46%
-0.59
Dopo l'orario di chiusura:
23.39
Precedente Chiudi:
$23.98
Aprire:
$23.99
Volume 24 ore:
782.18K
Relative Volume:
0.98
Capitalizzazione di mercato:
$2.63B
Reddito:
$14.09M
Utile/perdita netta:
$-176.94M
Rapporto P/E:
-10.88
EPS:
-2.15
Flusso di cassa netto:
$-141.24M
1 W Prestazione:
+6.41%
1M Prestazione:
+27.12%
6M Prestazione:
-0.89%
1 anno Prestazione:
+23.82%
Intervallo 1D:
$22.88
$24.06
Intervallo di 1 settimana:
$21.75
$24.18
Portata 52W:
$14.06
$27.29
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Confronta NAMS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
23.39 | 2.69B | 14.09M | -176.94M | -141.24M | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
Will NewAmsterdam Pharma Company N.V. Equity Warrant stock split in the near futureUnmatched market gains - jammulinksnews.com
What analysts say about NewAmsterdam Pharma Company N.V. Equity Warrant stockRobust investment performance - jammulinksnews.com
Arizona State Retirement System Buys New Shares in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Defense World
What analysts say about NewAmsterdam Pharma Company N.V. stockFree Stock Chart Pattern Guide - jammulinksnews.com
What drives NewAmsterdam Pharma Company N.V. stock priceRapid wealth creation - Autocar Professional
What makes NewAmsterdam Pharma Company N.V. stock price move sharplyDaily Breakout Picks - Newser
NewAmsterdam Pharma Company N.V. Equity Warrant Stock Analysis and ForecastHigh-impact stock picks - jammulinksnews.com
NewAmsterdam Pharma Company N.V. Stock Analysis and ForecastDouble-digit growth - jammulinksnews.com
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025 - GlobeNewswire
Major Alzheimer's Discovery: Cardiovascular Drug Shows Promising Brain Health Benefits in 1,727 Patients - Stock Titan
What drives NewAmsterdam Pharma Company N.V. Equity Warrant stock priceHigh-yield capital appreciation - jammulinksnews.com
How NewAmsterdam Pharma Company N.V. Equity Warrant stock performs during market volatilityFree High-Profit Stock Picks - Newser
Is NewAmsterdam Pharma Company N.V. Equity Warrant a good long term investmentExceptional return forecasts - Autocar Professional
Is NewAmsterdam Pharma Company N.V. a good long term investmentExplosive portfolio gains - jammulinksnews.com
why newamsterdam pharma company n.v. equity warrant stock attracts strong analyst attentionFree Risk Assessment Services - Newser
When is the best time to buy NewAmsterdam Pharma Company N.V. stockFree Access to Investment Community - Newser
NewAmsterdam Pharma (NASDAQ:NAMS) Coverage Initiated at The Goldman Sachs Group - Defense World
How NewAmsterdam Pharma Company N.V. stock reacts to Fed policy changesFree Capital Allocation Plans - Newser
Goldman Sachs Initiates Coverage on NewAmsterdam Pharma With Neutral Rating, $27 Price Target - MarketScreener
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating By Investing.com - Investing.com South Africa
Goldman Sachs initiates NewAmsterdam Pharma stock with Neutral rating - Investing.com Australia
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Receives $42.89 Consensus Price Target from Analysts - Defense World
Jefferies Remains Bullish on NewAmsterdam Pharma (NAMS) - MSN
12 Oversold NASDAQ Stocks to Buy Now - Insider Monkey
Why NewAmsterdam Pharma Company N.V. Equity Warrant stock attracts strong analyst attentionWatchlist Winner Update - Newser
Why NewAmsterdam Pharma Company N.V. stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How NewAmsterdam Pharma Company N.V. stock performs during market volatilityFree Stock Market Knowledge Sharing - Newser
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):